Literature DB >> 27845826

WITHDRAWN: Interventions for ear discharge associated with grommets (ventilation tubes).

Louise Vaile1, Tim Williamson, Angus Waddell, Gordon J Taylor.   

Abstract

BACKGROUND: The insertion of grommets (also known as ventilation or tympanostomy tubes) is one of the most common surgical procedures performed on children. Postoperative otorrhoea (discharge) is the most common complication with a reported incidence ranging from 10% to 50%. In the UK, many ENT surgeons treat with topical antibiotics/steroid combinations, but general practitioners, mainly through fears of ototoxicity, are unlikely to prescribe these and choose systemic broad-spectrum antibiotics.
OBJECTIVES: 1. To identify the most effective non-surgical management of discharge from ears with grommets in place.2. To identify the risks of non-surgical management for this condition (e.g. ototoxicity), and to set benefits of treatment against these risks. SEARCH
METHODS: We searched the Cochrane Ear, Nose and Throat Disorders Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 1, 2005), MEDLINE (1966 to 2005) and EMBASE (1974 to 2005). We also searched the CINAHL, AMED, LILACS, ISI WEB OF KNOWLEDGE, ISI PROCEEDINGS, mRCT, NNR, ZETOC, KOREAMED, CSA, MEDCARIB, INDMED and SAMED databases. The date of the last search was February 2005. SELECTION CRITERIA: Randomised controlled trials of adults or children, with any type of grommet and an ear with discharge were included. The trials compared treatment with placebo or one treatment with another. The primary outcome measure was the duration of the discharge. DATA COLLECTION AND ANALYSIS: The trials were selected independently according to the above criteria by the four reviewers. Differences in opinion over the inclusion of studies were resolved by discussion. The studies were graded using the CASP critical appraisal tool. Analyses were based on the presence of discharge seven days from the onset of treatment. MAIN
RESULTS: There was very little good quality evidence. Four studies were included, all of them investigating different interventions and therefore a meta-analysis was not possible.Only one study demonstrated a significant difference. Oral amoxicillin clavulanate was compared to placebo in 79 patients. The odds of having a discharge persisting eight days after starting treatment was 0.19 (95% CI 0.07 to 0.49) . The number needed to treat to achieve that benefit is 2.5. Participants in both arms of this study also received daily aural toilet. The results will therefore not be applicable to most settings including primary care. No significant benefit was shown in the two studies investigating steroids (oral prednisolone with oral amoxicillin clavulanate and topical dexamethasone with topical ciprofloxacin ear drops), or the one study comparing an antibiotic-steroid combination (Otosporin®) drops versus spray (Otomize®) (although more patients preferred the spray form). AUTHORS'
CONCLUSIONS: The authors of this review have been unable to identify the most effective intervention or to assess the associated risks. Research is urgently needed into the effectiveness of oral versus topical antibiotics in this group of patients. Clinicians considering antibiotic treatment need to balance any potential benefit against the risks of side effects and antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27845826      PMCID: PMC6734128          DOI: 10.1002/14651858.CD001933.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  18 in total

1.  Meta-analysis of tympanostomy tube sequelae.

Authors:  D J Kay; M Nelson; R M Rosenfeld
Journal:  Otolaryngol Head Neck Surg       Date:  2001-04       Impact factor: 3.497

2.  The effectiveness of topical treatment in discharging ears with in-dwelling ventilation tubes.

Authors:  D Strachan; S E Clarke; R J England
Journal:  Rev Laryngol Otol Rhinol (Bord)       Date:  2000

3.  Persistent otorrhoea after ventilation tube insertion: a treatment protocol.

Authors:  M A Siddiq; A A Narula
Journal:  Int J Clin Pract       Date:  2003-11       Impact factor: 2.503

Review 4.  Systemic antibiotics versus topical treatments for chronically discharging ears with underlying eardrum perforations.

Authors:  C A Macfadyen; J M Acuin; C Gamble
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

5.  Oral prednisolone is an effective adjuvant therapy for acute otitis media with discharge through tympanostomy tubes.

Authors:  A Ruohola; T Heikkinen; J Jero; T Puhakka; T Juvén; M Närkiö-Mäkelä; H Saxén; O Ruuskanen
Journal:  J Pediatr       Date:  1999-04       Impact factor: 4.406

6.  Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes.

Authors:  E L Goldblatt; J Dohar; R J Nozza; R W Nielsen; T Goldberg; J D Sidman; M Seidlin
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1998-11-15       Impact factor: 1.675

7.  Topical ofloxacin treatment of otorrhea in children with tympanostomy tubes.

Authors:  J E Dohar; E T Garner; R W Nielsen; M A Biel; M Seidlin
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1999-05

Review 8.  Topical antibiotics without steroids for chronically discharging ears with underlying eardrum perforations.

Authors:  C A Macfadyen; J M Acuin; C Gamble
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

9.  Topical ciprofloxacin/dexamethasone is superior to ciprofloxacin alone in pediatric patients with acute otitis media and otorrhea through tympanostomy tubes.

Authors:  Peter S Roland; Jack B Anon; Richard D Moe; Peter J Conroy; G Michael Wall; Sheryl J Dupre; Kimberly A Krueger; Susan Potts; Gail Hogg; David W Stroman
Journal:  Laryngoscope       Date:  2003-12       Impact factor: 3.325

10.  Antibiotic treatment of acute otorrhea through tympanostomy tube: randomized double-blind placebo-controlled study with daily follow-up.

Authors:  Aino Ruohola; Terho Heikkinen; Olli Meurman; Tuomo Puhakka; Niklas Lindblad; Olli Ruuskanen
Journal:  Pediatrics       Date:  2003-05       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.